Finance Watch: $320m In New VC Deals Includes $110m Round For Neogene
Also, Recursion Raises $239m, Including $50m From New Partner Bayer
Executive Summary
Private Company Edition: Neogene, Escient, ESCAPE, Resolution and Attralus raised a combined $320m in venture capital rounds. Also, large Recursion round could double the size of its pipeline, Korro Bio raised $91.5m and Flagship launched Generate Biomedicines.
You may also be interested in...
Alentis Aims To Put The Brakes On Fibrosis
Building on 20 years of work and positive preclinical data, and backed by a fresh injection of cash, Alentis is taking its liver fibrosis candidate into Phase I trials in the fourth quarter.
Finance Watch: Two SPAC Deals, Two IPOs Take Four Biopharmas Public
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Finance Watch: Biopharma VC Explosion Extends To Tools, Services
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.